Company overview Financial review Conclusions Appendix References 1 Investor Relations │ Q1 2023 Results f Q1 2023 Results Investor presentation U NOVARTIS | Reimagining Medicine Company overview Financial review Conclusions Appendix References 2 NOVARTIS Q1 RESULTS | APRIL 25, 2023 | NOVARTIS INVESTOR PRESENTATION Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by word ...